Online citations, reference lists, and bibliographies.

Riluzole For Amyotrophic Lateral Sclerosis (ALS)/motor Neuron Disease (MND).

R. Miller, J. Mitchell, D. Moore
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy. OBJECTIVES To examine the efficacy of riluzole in prolonging survival and in delaying the use of surrogates (tracheostomy and mechanical ventilation) to sustain survival, and to assess the effect of riluzole upon functional health. SEARCH METHODS We searched the Cochrane Neuromuscular Disease Group Specialized Register (20 April 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) (2011, Issue 2), MEDLINE (1966 to April 2011), EMBASE (1980 to May 2011) and made enquiries of authors of trials, Aventis (manufacturer of riluzole) and other experts in the field. SELECTION CRITERIA Types of studies: randomized controlled trials TYPES OF PARTICIPANTS adults with a diagnosis of amyotrophic lateral sclerosis Types of interventions: treatment with riluzole or placebo Types of outcome measures: Primary: pooled hazard ratio of tracheostomy-free survival over all time points with riluzole 100 mg. Secondary: per cent mortality with riluzole 50 mg, 100 mg and 200 mg; neurologic function, muscle strength and adverse events. DATA COLLECTION AND ANALYSIS One author performed data extraction and two other authors checked them. One author checked the data and entered them into the computer. The other authors verified the data entry. We obtained missing data from the trial authors whenever possible. MAIN RESULTS The four trials examining tracheostomy-free survival included a total of 974 riluzole-treated patients and 503 placebo-treated patients. No new randomized controlled trials were found when we updated the searches for this update in 2011. The methodological quality was acceptable and three trials were easily comparable, although one trial (169 participants) included older patients in more advanced stages of amyotrophic lateral sclerosis and one (195 participants) had multiple primary endpoints. Riluzole 100 mg per day provided a benefit for the homogeneous group of patients in the first two trials (hazard ratio (HR) 0.80, 95% confidence internal (CI) 0.64 to 0.99, P= 0.042) and there was no evidence of heterogeneity (P = 0.33). When the third trial (which included older and more seriously affected patients) was added, there was evidence of heterogeneity (P < 0.0001) and the overall treatment effect was reduced but still significant (HR 0.84, 95% CI 0.698 to 0.997, P= 0.046). This represented a 9% gain in the probability of surviving one year (49% in the placebo and 58% in the riluzole group), and increased median survival from 11.8 to 14.8 months. There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. A three-fold increase in serum alanine transferase was more frequent in riluzole-treated patients than controls (mean difference 2.62, 95% CI 1.59 to 4.31). AUTHORS' CONCLUSIONS Riluzole 100 mg daily is reasonably safe and probably prolongs median survival by about two to three months in patients with amyotrophic lateral sclerosis.
This paper references
10.1212/WNL.46.5.1442
Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS
D. McGuire (1996)
10.1016/S1579-2129(06)60113-4
[Strong suspicion of lung toxicity due to riluzole].
L. Borderías-Clau (2006)
The Kings’ Database 1999-2000: an analysis of the effect on survival of interventions in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron
MR Turner 2001 Turner (2000)
10.1016/S0022-510X(99)00225-7
The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation
M. Desiato (1999)
10.1212/WNL.52.7.1311
Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)
R. Miller (1999)
10.1212/WNL.39.12.1635
A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis
L. Lacomblez (1989)
10.1212/WNL.0b013e3181bc0141
Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review)
R. Miller (2009)
10.1016/S0959-4388(96)80103-6
Therapeutic horizons for amyotrophic lateral sclerosis
J. Rothstein (1996)
Riluzole and prognosis in ALS: Findings of the Irish ALS register over a five year study period
BJ Traynor 2001 Traynor (1999)
10.1097/00001756-199806010-00016
Recovery of N‐acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy
S. Kalra (1998)
10.1111/j.1572-0241.2001.03982.x
Riluzole-induced acute pancreatitis
L. Rodrigo (2001)
Open label study of riluzole for the treatment of amyotrophic lateral sclerosis
N. A. Mendicoa (1999)
10.1046/J.1529-8027.2000.00513-45.X
AN OPEN STUDY OF RILUZOLE VERSUS RILUZOLE PLUS GABAPENTIN IN AMYOTROPHIC LATERAL SCLEROSIS
V. Palma (2000)
10.1157/13083280
Alta sospecha de toxicidad pulmonar por riluzol
L. Borderías-Clau (2006)
10.1080/17482960701223030
Efficacy of riluzole: Who are the patients enrolled in the studies?
G. Logroscino (2007)
10.1016/0022-510X(94)90191-0
El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
B. Brooks (1994)
10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
M. K. Parmar (1998)
10.1212/WNL.50.1.66
Prognostic indicators of survival in ALS
N. Stambler (1998)
10.1080/14660820410019602
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
V. Meininger (2004)
10.1007/s004150200071
A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis
G. Bensimon (2002)
10.1016/S0168-8278(99)80115-9
Acute hepatitis after riluzole administration.
A. Remy (1999)
10.1055/S-2007-1017633
Offene Therapiestudie zur Verträglichkeit von Riluzol bei Patienten mit amyotropher Lateralsklerose (ALS)
D. Pongratz (1999)
10.1016/S1474-4422(05)70326-4
Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial
S. Bourke (2006)
Riluzole and ALS therapy.
J. Hugon (1996)
10.1136/BMJ.322.7297.1305
Riluzole for motor neurone disease
J. Sandercock (2001)
10.1056/NEJM199403033300901
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
G. Bensimon (1994)
10.3310/HTA5020
The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
A. Stewart (2001)
10.1212/WNL.47.6_Suppl_4.251S
ALS therapy
J. Hugon (1996)
10.1080/14660820500396984
Audit of outcomes in motor neuron disease (MND) patients treated with riluzole
Douglas J. Mitchell (2006)
10.1016/S0140-6736(05)60977-4
Effects of riluzole on symptom progression in amyotrophic lateral sclerosis
P. Sojka (1997)
10.1002/9780470712184.CH8
Assessing Risk of Bias in Included Studies
J. P. Higgins (2008)
10.1001/ARCHNEUR.55.4.526
An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.
M. Rivière (1998)
10.1212/01.WNL.0000123015.48097.9A
Riluzole-induced neutropenia
G. Weber (2004)
10.1111/j.1468-1331.2006.01575.x
Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy
S. Zoccolella (2007)
10.1056/NEJM199403033300911
Riluzole for the treatment of amyotrophic lateral sclerosis--too soon to tell?
L. Rowland (1994)
[Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS].
P. Couratier (2000)
10.1016/S0140-6736(96)91680-3
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral SclerosisRiluzole Study Group (1996)
10.1007/BF03160577
The Riluzole Early Access Programme: descriptive analysis of 844 patients in France
V. Meininger (2009)
10.1212/01.wnl.0000249182.09143.20
An acute, life-threatening, hypersensitivity reaction to riluzole
E. Sorenson (2006)
10.1007/s00702-004-0220-1
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study
M. Graf (2004)
10.1212/01.WNL.0000082385.33604.1D
Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS
D. Cassiman (2003)
10.1212/WNL.47.4_Suppl_2.86S
Clinical trials of riluzole in patients with ALS
R. Miller (1996)



This paper is referenced by
10.1016/j.pharmthera.2011.05.006
Current and future therapeutic strategies for functional repair of spinal cord injury.
C. Tohda (2011)
10.1016/j.ijbiomac.2020.01.032
Computational insights into mechanism of AIM4-mediated inhibition of aggregation of TDP-43 protein implicated in ALS and evidence for in vitro inhibition of liquid-liquid phase separation (LLPS) of TDP-432C-A315T by AIM4.
Amandeep Girdhar (2020)
POTENCIAL TERAPÊUTICO DAS CÉLULAS MONONUCLEARES DA MEDULA ÓSSEA EM UM MODELO EXPERIMENTAL DE ESCLEROSE LATERAL AMIOTRÓFICA
G. T. Venturin (2012)
10.1007/s12035-017-0707-z
Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease
Kevin M. Budge (2017)
10.1016/j.pneurobio.2015.06.004
Toward therapeutic targets for SCA3: Insight into the role of Machado–Joseph disease protein ataxin-3 in misfolded proteins clearance
Xiaoling Li (2015)
10.1016/B978-0-12-397179-1.00021-X
Molecular Mechanisms of Neurological Disease
Monica Gireud (2014)
10.1021/jm500065f
Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis
Irene G. Salado (2014)
10.1007/978-3-319-42297-8_16
Predicting Progression of ALS Disease with Random Frog and Support Vector Regression Method
Shu-Lin Wang (2016)
10.3171/2018.9.SPINE18682
Time is spine: a review of translational advances in spinal cord injury.
J. Badhiwala (2018)
10.1186/scrt421
Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis
Christina M. Lewis (2014)
10.3390/jpm8040044
Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge
Stephen Morgan (2018)
Prediction of Patient Outcomes after Traumatic Spinal Cord Injury using Acute Clinical and Radiological Variables
Jefferson Wilson (2013)
10.1007/978-3-319-63309-1_22
Research on Feature Selection and Predicting ALS Disease Progression
Jin Li (2017)
10.2196/12046
The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial
Ryosuke Oki (2018)
10.3109/21678421.2015.1026826
A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement
Zachary Macchi (2015)
THE PROTECTIVE ROLE OF NRF2/KEAP1 IN NEUROLOGICAL DISEASE AND OXIDATIVE STRESS-INDUCED CELL DAMAGE
P. Bergström (2013)
10.1016/j.expneurol.2011.11.008
Nerve excitability changes related to axonal degeneration in amyotrophic lateral sclerosis: Insights from the transgenic SOD1G127X mouse model
M. Moldovan (2012)
10.1016/j.wneu.2018.02.171
Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury.
Y. Caglar (2018)
10.3390/jcm8101719
Reformulating Pro-Oxidant Microglia in Neurodegeneration
Juan García-Revilla (2019)
10.1007/978-1-4471-4171-6_25
Treatment by Human Fetal Neuronal Tissue Transplant at a Heterotopic Site in the Axilla in Case of Motor Neuron Disease: A Report of Two Cases
Niranjan Bhattacharya (2013)
10.1016/j.ejmech.2016.08.006
Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review.
Hena Khanam (2016)
10.1016/S1474-4422(17)30009-1
Blockade of the neurite outgrowth inhibitor Nogo-A in amyotrophic lateral sclerosis
Anne-Marie A Wills (2017)
10.1016/J.FMC.2016.11.005
Qué sabemos de la esclerosis lateral amiotrófica
Silvia Alcalde Muñoz (2017)
Practice Points Barriers to novel therapeutics in amyotrophic lateral sclerosis MANAGEMENT PERSPECTIVE
Xenia Kobeleva (2013)
10.1007/s40263-013-0068-8
Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic
S. Mi (2013)
10.1016/j.bbadis.2013.03.012
Rodent models of amyotrophic lateral sclerosis.
P. Mcgoldrick (2013)
10.1016/j.nmd.2013.08.001
Cochrane 20years on: The Cochrane Neuromuscular Disease Group
Michael Pt Lunn (2013)
10.1007/978-1-4939-7228-9_7
Drugs to Alter Extracellular Concentration of Glutamate: Modulators of Glutamate Uptake Systems
Andreia Cristina Karklin Fontana (2018)
10.5772/INTECHOPEN.84695
Contribution of Aberrant Astrocytes to Motor Neuron Damage and Death in the SOD1G93A Rat Experimental Model of ALS
Gabriel Otero Damianovich (2019)
10.1016/j.jns.2019.116650
Riluzole-induced interstitial lung disease is a rare and potentially life-threatening adverse event successfully treated with high-dose steroid therapy: Case reports and review of the literature
Yuji Saitoh (2020)
10.1016/B978-0-12-800105-9.00042-1
Amyotrophic Lateral Sclerosis 1 and Many Diseases
E. Ratti (2016)
10.1002/bimj.201500236
Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases
T. Friede (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar